Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity raises target price on Greatland Gold

(Sharecast News) - Analysts at Canaccord Genuity slightly raised their target price on gold and copper producer Greatland Gold from 25.0p to 29.0p on Tuesday following its Telfer-Havieron site visit. Canaccord Genuity said it had returned from Telfer-Havieron with "a more positive view" on the near and medium-term outlook for the company.

In the near term, Canaccord noted that Greatland was performing well in the current quarter, while it also said there were "a range of likely life extension options" for Telfer in the medium term via the Central and Southern extensions, the Main Dome Underground, and West Dome Deeps. Long-term, Canaccord said Havieron was likely to be "significantly bigger, at a modest additional cost".

In its time at the site, Canaccord also attempted to identify key risks to the development plan and the critical path focus. In its view, water management at Havieron will be the key focus, in addition to managing the tailings facilities.

"We have adjusted our numbers for the production assumptions detailed above. This has resulted in minimal changes over the near-term, but we see a 29p net asset value/shr as a result of the Telfer life extension and the Havieron expansion being brought into our base case," said the Canadian bank, which reiterated its 'buy' rating on the stock.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.